Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Launay

Showing results (11-20 of 307) with videos related to

Pageof 31
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|June 30, 2025
Absence of functional autoantibodies in systemic sclerosis: is now the right time to broaden reactome analysis? Comment on "Absence of Functional Autoantibodies Targeting Angiotensin II Receptor Type 1 and Endothelin-1 Type A Receptor in Circulation and Purified IgG From Patients With Systemic Sclerosis" published in Arthritis RheumatologyAurélien Chepy, Sylvain Dubucquoi, David Launay, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|September 29, 2017
Pulmonary hypertension in systemic sclerosis: different phenotypesDavid Launay, Vincent Sobanski, Eric Hachulla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Role of iconographic examinations in the treatment algorithm in Erdheim-Chester diseaseAchille Aouba, Boris Bienvenu, David Launay, et al.
Journal of Translational Autoimmunity|February 7, 2025
Autoantibodies in systemic sclerosis: From disease bystanders to pathogenic playersAurélien Chepy, Aurore Collet, David Launay, et al.
Acta Neurologica Belgica|August 2, 2013
Mixed connective tissue disease presenting as trigeminal neuropathyBertrand Hamoir, Marianne Giroux, Olivier Outteryck, et al.
Seminars in Nuclear Medicine|April 21, 2026
[<sup>18</sup>F]FDG PET/CT imaging in Polyarteritis Nodosa-spectrum vasculitisNicolas Martinage, Emmanuel Ledoult, Clio Baillet, et al.
European Journal of Cancer (Oxford, England : 1990)|March 3, 2022
The letter responds to comment on: Anti-PD(L)1 immunotherapies in patients with cancer and with pre-existing systemic sclerosis: a post-marketed safety assessment studyMarion Panhaleux, David Launay, Nicolas Penel, et al.
Autoimmunity Reviews|March 1, 2020
Are pregnancies with lupus but without APS of good prognosis?Aurore Marx-Deseure, Julien Labreuche, David Launay, et al.
Joint Bone Spine|January 9, 2023
Use of avacopan in severe forms of ANCA-associated vasculitis. Comment on "Inhibiting C5a/C5aR to treat ANCA-associated vasculitides" by Terrier et al. Joint Bone Spine 2023;90:105472Quentin Astouati, François Provot, Meryem-Maud Farhat, et al.
Acta Dermato-Venereologica|November 9, 2007
Periorbital ecchymoses are not pathognomonic of the light-chain type of amyloidosisOlivier Outteryck, Tanya Stojkovic, David Launay, et al.
Pageof 31

Showing results (11-20 of 307) with videos related to

Sort By:
Pageof 31
Arthritis & Rheumatology (Hoboken, N.J.)|June 30, 2025
Absence of functional autoantibodies in systemic sclerosis: is now the right time to broaden reactome analysis? Comment on "Absence of Functional Autoantibodies Targeting Angiotensin II Receptor Type 1 and Endothelin-1 Type A Receptor in Circulation and Purified IgG From Patients With Systemic Sclerosis" published in Arthritis RheumatologyAurélien Chepy, Sylvain Dubucquoi, David Launay, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|September 29, 2017
Pulmonary hypertension in systemic sclerosis: different phenotypesDavid Launay, Vincent Sobanski, Eric Hachulla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Role of iconographic examinations in the treatment algorithm in Erdheim-Chester diseaseAchille Aouba, Boris Bienvenu, David Launay, et al.
Journal of Translational Autoimmunity|February 7, 2025
Autoantibodies in systemic sclerosis: From disease bystanders to pathogenic playersAurélien Chepy, Aurore Collet, David Launay, et al.
Acta Neurologica Belgica|August 2, 2013
Mixed connective tissue disease presenting as trigeminal neuropathyBertrand Hamoir, Marianne Giroux, Olivier Outteryck, et al.
Seminars in Nuclear Medicine|April 21, 2026
[<sup>18</sup>F]FDG PET/CT imaging in Polyarteritis Nodosa-spectrum vasculitisNicolas Martinage, Emmanuel Ledoult, Clio Baillet, et al.
European Journal of Cancer (Oxford, England : 1990)|March 3, 2022
The letter responds to comment on: Anti-PD(L)1 immunotherapies in patients with cancer and with pre-existing systemic sclerosis: a post-marketed safety assessment studyMarion Panhaleux, David Launay, Nicolas Penel, et al.
Autoimmunity Reviews|March 1, 2020
Are pregnancies with lupus but without APS of good prognosis?Aurore Marx-Deseure, Julien Labreuche, David Launay, et al.
Joint Bone Spine|January 9, 2023
Use of avacopan in severe forms of ANCA-associated vasculitis. Comment on "Inhibiting C5a/C5aR to treat ANCA-associated vasculitides" by Terrier et al. Joint Bone Spine 2023;90:105472Quentin Astouati, François Provot, Meryem-Maud Farhat, et al.
Acta Dermato-Venereologica|November 9, 2007
Periorbital ecchymoses are not pathognomonic of the light-chain type of amyloidosisOlivier Outteryck, Tanya Stojkovic, David Launay, et al.
Pageof 31